185 related articles for article (PubMed ID: 29127277)
21. Docking simulation with a purine nucleoside specific homology model of deoxycytidine kinase, a target enzyme for anticancer and antiviral therapy.
Johnsamuel J; Eriksson S; Oliveira M; Tjarks W
Bioorg Med Chem; 2005 Jul; 13(13):4160-7. PubMed ID: 15876539
[TBL] [Abstract][Full Text] [Related]
22. Gemcitabine resistance due to deoxycytidine kinase deficiency can be reverted by fruitfly deoxynucleoside kinase, DmdNK, in human uterine sarcoma cells.
Jordheim LP; Galmarini CM; Dumontet C
Cancer Chemother Pharmacol; 2006 Oct; 58(4):547-54. PubMed ID: 16463058
[TBL] [Abstract][Full Text] [Related]
23. Structural characterization of new deoxycytidine kinase inhibitors rationalizes the affinity-determining moieties of the molecules.
Nomme J; Murphy JM; Su Y; Sansone ND; Armijo AL; Olson ST; Radu C; Lavie A
Acta Crystallogr D Biol Crystallogr; 2014 Jan; 70(Pt 1):68-78. PubMed ID: 24419380
[TBL] [Abstract][Full Text] [Related]
24. Interaction between gemcitabine and topotecan in human non-small-cell lung cancer cells: effects on cell survival, cell cycle and pharmacogenetic profile.
Giovannetti E; Mey V; Danesi R; Basolo F; Barachini S; Deri M; Del Tacca M
Br J Cancer; 2005 Feb; 92(4):681-9. PubMed ID: 15700043
[TBL] [Abstract][Full Text] [Related]
25. Activation of deoxycytidine kinase by protein kinase inhibitors and okadaic acid in leukemic cells.
Smal C; Cardoen S; Bertrand L; Delacauw A; Ferrant A; Van den Berghe G; Van Den Neste E; Bontemps F
Biochem Pharmacol; 2004 Jul; 68(1):95-103. PubMed ID: 15183121
[TBL] [Abstract][Full Text] [Related]
26. Quantitative Targeted Proteomics of Pancreatic Cancer: Deoxycytidine Kinase Protein Level Correlates to Progression-Free Survival of Patients Receiving Gemcitabine Treatment.
Ohmine K; Kawaguchi K; Ohtsuki S; Motoi F; Ohtsuka H; Kamiie J; Abe T; Unno M; Terasaki T
Mol Pharm; 2015 Sep; 12(9):3282-91. PubMed ID: 26280109
[TBL] [Abstract][Full Text] [Related]
27. Immunohistochemical and genetic evaluation of deoxycytidine kinase in pancreatic cancer: relationship to molecular mechanisms of gemcitabine resistance and survival.
Sebastiani V; Ricci F; Rubio-Viqueira B; Kulesza P; Yeo CJ; Hidalgo M; Klein A; Laheru D; Iacobuzio-Donahue CA
Clin Cancer Res; 2006 Apr; 12(8):2492-7. PubMed ID: 16638857
[TBL] [Abstract][Full Text] [Related]
28. The apoptotic effects of toosendanin are partially mediated by activation of deoxycytidine kinase in HL-60 cells.
Ju J; Qi Z; Cai X; Cao P; Huang Y; Wang S; Liu N; Chen Y
PLoS One; 2012; 7(12):e52536. PubMed ID: 23300702
[TBL] [Abstract][Full Text] [Related]
29. Structural and kinetic characterization of human deoxycytidine kinase variants able to phosphorylate 5-substituted deoxycytidine and thymidine analogues .
Hazra S; Ort S; Konrad M; Lavie A
Biochemistry; 2010 Aug; 49(31):6784-90. PubMed ID: 20614893
[TBL] [Abstract][Full Text] [Related]
30. Casein kinase 1delta activates human recombinant deoxycytidine kinase by Ser-74 phosphorylation, but is not involved in the in vivo regulation of its activity.
Smal C; Vertommen D; Amsailale R; Arts A; Degand H; Morsomme P; Rider MH; Neste EV; Bontemps F
Arch Biochem Biophys; 2010 Oct; 502(1):44-52. PubMed ID: 20637175
[TBL] [Abstract][Full Text] [Related]
31. Cytotoxic activity of 2',2'-difluorodeoxycytidine, 5-aza-2'-deoxycytidine and cytosine arabinoside in cells transduced with deoxycytidine kinase gene.
Beauséjour CM; Gagnon J; Primeau M; Momparler RL
Biochem Biophys Res Commun; 2002 May; 293(5):1478-84. PubMed ID: 12054682
[TBL] [Abstract][Full Text] [Related]
32. [Special function of deoxycytidine kinase (dCK) in the activation of chemotherapeutic nucleoside analogs and in the inhibition of cell proliferation].
Staub M
Magy Onkol; 2004; 48(3):229-34. PubMed ID: 15520873
[TBL] [Abstract][Full Text] [Related]
33. Regulation of phosphorylation of deoxycytidine and 2',2'-difluorodeoxycytidine (gemcitabine); effects of cytidine 5'-triphosphate and uridine 5'-triphosphate in relation to chemosensitivity for 2',2'-difluorodeoxycytidine.
van Haperen VW; Veerman G; Vermorken JB; Pinedo HM; Peters G
Biochem Pharmacol; 1996 Apr; 51(7):911-8. PubMed ID: 8651941
[TBL] [Abstract][Full Text] [Related]
34. Cyclopentenyl cytosine-induced activation of deoxycytidine kinase increases gemcitabine anabolism and cytotoxicity in neuroblastoma.
Bierau J; van Gennip AH; Leen R; Meinsma R; Caron HN; van Kuilenburg AB
Cancer Chemother Pharmacol; 2006 Jan; 57(1):105-13. PubMed ID: 16133534
[TBL] [Abstract][Full Text] [Related]
35. Down-regulation of deoxycytidine kinase enhances acquired resistance to gemcitabine in pancreatic cancer.
Ohhashi S; Ohuchida K; Mizumoto K; Fujita H; Egami T; Yu J; Toma H; Sadatomi S; Nagai E; Tanaka M
Anticancer Res; 2008; 28(4B):2205-12. PubMed ID: 18751396
[TBL] [Abstract][Full Text] [Related]
36. Structure-guided development of deoxycytidine kinase inhibitors with nanomolar affinity and improved metabolic stability.
Nomme J; Li Z; Gipson RM; Wang J; Armijo AL; Le T; Poddar S; Smith T; Santarsiero BD; Nguyen HA; Czernin J; Alexandrova AN; Jung ME; Radu CG; Lavie A
J Med Chem; 2014 Nov; 57(22):9480-94. PubMed ID: 25341194
[TBL] [Abstract][Full Text] [Related]
37. All-trans retinoic acid enhances gemcitabine cytotoxicity in human pancreatic cancer cell line AsPC-1 by up-regulating protein expression of deoxycytidine kinase.
Kuroda H; Tachikawa M; Uchida Y; Inoue K; Ohtsuka H; Ohtsuki S; Unno M; Terasaki T
Eur J Pharm Sci; 2017 May; 103():116-121. PubMed ID: 28215943
[TBL] [Abstract][Full Text] [Related]
38. Structural basis for activation of the therapeutic L-nucleoside analogs 3TC and troxacitabine by human deoxycytidine kinase.
Sabini E; Hazra S; Konrad M; Burley SK; Lavie A
Nucleic Acids Res; 2007; 35(1):186-92. PubMed ID: 17158155
[TBL] [Abstract][Full Text] [Related]
39. Sensitization of ara-C-resistant lymphoma cells by a pronucleotide analogue.
Galmarini CM; Clarke ML; Santos CL; Jordheim L; Perigaud C; Gosselin G; Cros E; Mackey JR; Dumontet C
Int J Cancer; 2003 Oct; 107(1):149-54. PubMed ID: 12925971
[TBL] [Abstract][Full Text] [Related]
40. Targeting Casein Kinase 1 Delta Sensitizes Pancreatic and Bladder Cancer Cells to Gemcitabine Treatment by Upregulating Deoxycytidine Kinase.
Vena F; Bayle S; Nieto A; Quereda V; Aceti M; Frydman SM; Sansil SS; Grant W; Monastyrskyi A; McDonald P; Roush WR; Teng M; Duckett D
Mol Cancer Ther; 2020 Aug; 19(8):1623-1635. PubMed ID: 32430484
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
